Baird Maintains Castle Biosciences(CSTL.US) With Buy Rating, Raises Target Price to $39

貝雅維持Castle Biosciences(CSTL.US)買入評級，上調目標價至39美元

moomoo資訊 · 2024/11/05 20:35 · 評級/大行評級

Baird analyst Catherine Ramsey Schulte maintains $Castle Biosciences (CSTL.US)$ with a buy rating, and adjusts the target price from $37 to $39.

According to TipRanks data, the analyst has a success rate of 54.5% and a total average return of 12.4% over the past year.

AnalystRecentRatingAutoNews_77704548536000_20241105_0569c2fe1d7f0c3d05c0808d3ab82dadef3aeb71_1730809870243101_mm_en

Furthermore, according to the comprehensive report, the opinions of $Castle Biosciences (CSTL.US)$'s main analysts recently are as follows:

Castle Biosciences reported a robust third quarter, with revenues meeting expectations and showing promising operational expenditure leverage. The company experienced overall volume growth, although dermatology volumes fell short of estimates because of seasonal factors. Meanwhile, the TissueCypher product continued to display significant momentum.
The company's continuous expansion of volumes for its variety of tests, including growth seen in IDgenetix and TissueCypher, has been a contributing factor to the robust quarterly results and the elevated revenue forecasts.

Note:

TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.

Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.

TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.

貝雅分析師Catherine Ramsey Schulte維持$Castle Biosciences (CSTL.US)$買入評級，並將目標價從37美元上調至39美元。

根據TipRanks數據顯示，該分析師近一年總勝率為54.5%，總平均回報率為12.4%。

AnalystRecentRatingAutoNews_77704548536000_20241105_0569c2fe1d7f0c3d05c0808d3ab82dadef3aeb71_1730809870243101_mm_tc

此外，綜合報道，$Castle Biosciences (CSTL.US)$近期主要分析師觀點如下：

Castle Biosciences報告了一個強勁的第三季度，營業收入符合預期，並顯示出有希望的運營費用槓桿。該公司經歷了總體成交量增長，儘管由於季節因素，皮膚病學成交量未達預期。與此同時，TissueCypher產品繼續顯示出顯着的增長勢頭。
公司不斷擴大各種測試的成交量，包括在IDgenetix和TissueCypher中看到的增長，已成爲強勁季度業績和提高營業收入預測的一個因素。

提示:

TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。

TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。

分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。

總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。更多信息

Baird Maintains Castle Biosciences(CSTL.US) With Buy Rating, Raises Target Price to $39

Baird Maintains Castle Biosciences(CSTL.US) With Buy Rating, Raises Target Price to $39

風險及免責聲明

聲明